CoStim

CoStim Pharmaceuticals was a private biotechnology company based in Cambridge, Massachusetts, dedicated to the development of novel cancer immunotherapies. The company focused on the identification and characterization of monoclonal antibodies that target T-cell costimulatory and coinhibitory receptors, which play a critical role in the body's immune response to tumors. Its research was primarily based on the work of prominent scientists from the Dana-Farber Cancer Institute and Harvard Medical School. CoStim's pipeline featured promising programs targeting PD-1, LAG-3, and TIM-3, positioning it at the forefront of the checkpoint inhibitor field. In February 2014, Novartis acquired CoStim Pharmaceuticals to significantly enhance its oncology portfolio and accelerate its entry into the competitive immuno-oncology market. The acquisition allowed Novartis to integrate CoStim's early-stage assets into its broader drug development infrastructure.